Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma, Transitional Cell Cancer, Wilms Tumor, Renal Sarcoma), by Therapy, by Drug Class, by Route of Administration, by End Use, and Regional Forecasts 2022-2032

Description

The global kidney cancer drugs market was valued at USD 6.25 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.9% over the forecast period from 2024 to 2032. This growth is primarily driven by advancements in immunotherapy and targeted therapies, which are revolutionizing treatment outcomes for patients with kidney cancer. Additionally, the increasing prevalence of renal cell carcinoma (RCC), coupled with the rise in healthcare expenditure, is fostering market growth.

Renal Cell Carcinoma (RCC) is the leading type of kidney cancer, contributing to 85.8% of market revenue in 2023. This is attributed to aging demographics, lifestyle-related risk factors, and improvements in diagnostic techniques enabling early detection. Immunotherapies and targeted treatments are anticipated to expand further, offering a more patient-centric approach with minimized side effects compared to traditional chemotherapies.

Geographically, North America dominated the kidney cancer drugs market in 2023, supported by robust healthcare infrastructure and access to cutting-edge treatments. The Asia-Pacific region, however, is projected to grow at the fastest rate, owing to increasing healthcare access and awareness campaigns. Rising adoption of biosimilars and innovative drug pipelines also present promising opportunities for market players in emerging economies.

Major market players included in this report are:

Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
GSK plc
Helsinn Healthcare SA
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG

The detailed segments and sub-segments of the market are explained below:

By Type

Renal Cell Carcinoma (RCC)
Transitional Cell Cancer
Wilms Tumor
Renal Sarcoma

By Therapy

Targeted Therapy
Immunotherapy
Chemotherapy
Other Therapies

By Drug Class

Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)
Other Drug Classes

By Route of Administration

Oral
Intravenous
Subcutaneous

By End Use

Hospital Pharmacies
Retail Pharmacies
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market estimates & forecasts for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Kidney Cancer Drugs Market Executive Summary

1.1. Global Kidney Cancer Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Therapy
- 1.3.3. By Drug Class
- 1.3.4. By Route of Administration
- 1.3.5. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Kidney Cancer Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Kidney Cancer Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Kidney Cancer Incidence Rates
- 3.1.2. Advancements in Immunotherapy and Targeted Therapy
- 3.1.3. Increase in Healthcare Spending and Awareness Campaigns
3.2. Market Challenges
- 3.2.1. High Costs and Side Effects of Kidney Cancer Drugs
- 3.2.2. Regulatory Complexities in Drug Approvals
3.3. Market Opportunities
- 3.3.1. Emerging Markets with Undiagnosed Populations
- 3.3.2. Expansion of Biosimilars

Chapter 4. Global Kidney Cancer Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Kidney Cancer Drugs Market Size & Forecasts by Type (2022-2032)

5.1. Segment Dashboard
5.2. Global Kidney Cancer Drugs Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Renal Cell Carcinoma (RCC)
- 5.2.2. Transitional Cell Cancer
- 5.2.3. Wilms Tumor
- 5.2.4. Renal Sarcoma

Chapter 6. Global Kidney Cancer Drugs Market Size & Forecasts by Therapy (2022-2032)

6.1. Segment Dashboard
6.2. Global Kidney Cancer Drugs Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Targeted Therapy
- 6.2.2. Immunotherapy
- 6.2.3. Chemotherapy
- 6.2.4. Other Therapies

Chapter 7. Global Kidney Cancer Drugs Market Size & Forecasts by Drug Class (2022-2032)

7.1. Segment Dashboard
7.2. Global Kidney Cancer Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Angiogenesis Inhibitors
- 7.2.2. Monoclonal Antibodies
- 7.2.3. mTOR Inhibitors
- 7.2.4. Cytokine Immunotherapy (IL-2)
- 7.2.5. Other Drug Classes

Chapter 8. Global Kidney Cancer Drugs Market Size & Forecasts by Route of Administration (2022-2032)

8.1. Segment Dashboard
8.2. Global Kidney Cancer Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Oral
- 8.2.2. Intravenous
- 8.2.3. Subcutaneous

Chapter 9. Global Kidney Cancer Drugs Market Size & Forecasts by End Use (2022-2032)

9.1. Segment Dashboard
9.2. Global Kidney Cancer Drugs Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 9.2.1. Hospital Pharmacies
- 9.2.2. Retail Pharmacies
- 9.2.3. Others

Chapter 10. Global Kidney Cancer Drugs Market Size & Forecasts by Region (2022-2032)

10.1. North America Kidney Cancer Drugs Market
- 10.1.1. U.S. Kidney Cancer Drugs Market
- 10.1.2. Canada Kidney Cancer Drugs Market
- 10.1.3. Mexico Kidney Cancer Drugs Market
10.2. Europe Kidney Cancer Drugs Market
- 10.2.1. UK Kidney Cancer Drugs Market
- 10.2.2. Germany Kidney Cancer Drugs Market
- 10.2.3. France Kidney Cancer Drugs Market
- 10.2.4. Italy Kidney Cancer Drugs Market
- 10.2.5. Spain Kidney Cancer Drugs Market
10.3. Asia Pacific Kidney Cancer Drugs Market
- 10.3.1. China Kidney Cancer Drugs Market
- 10.3.2. Japan Kidney Cancer Drugs Market
- 10.3.3. India Kidney Cancer Drugs Market
- 10.3.4. Australia Kidney Cancer Drugs Market
- 10.3.5. South Korea Kidney Cancer Drugs Market
10.4. Latin America Kidney Cancer Drugs Market
- 10.4.1. Brazil Kidney Cancer Drugs Market
- 10.4.2. Argentina Kidney Cancer Drugs Market
10.5. Middle East & Africa Kidney Cancer Drugs Market
- 10.5.1. Saudi Arabia Kidney Cancer Drugs Market
- 10.5.2. South Africa Kidney Cancer Drugs Market

Chapter 11. Competitive Intelligence

11.1. Key Company SWOT Analysis
- 11.1.1. Astellas Pharma Inc.
- 11.1.2. F. Hoffmann-La Roche Ltd.
- 11.1.3. Merck & Co., Inc.
11.2. Top Market Strategies
11.3. Company Profiles

Chapter 12. Research Process

12.1. Research Process Overview
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation